Conditions

This post was originally published on this site New research using “big data” helps highlight the differences between breast cancer cell lines and actual patient samples. This could allow researchers to choose models that more accurately reflect what actually happens in people. The study, “Evaluating cell lines as models for metastatic breast cancer through integrative…

This post was originally published on this site Prophylactic anti-TNF therapy improves the safety and, to some degree, the efficacy of checkpoint blockade combination immunotherapies, a mouse study says. The findings of the study, “Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy,” were published in Nature. Previous studies have shown…

This post was originally published on this site Updated results from two clinical trials support the potential of AFM13, an  investigational immunotherapy being developed by Affimed, in combination with Merck‘s Keytruda (pembrolizumab) for patients with Hodgkin’s lymphoma, or as a single agent for people with CD30-positive skin lymphomas who failed standard therapies. The data were…

This post was originally published on this site Foes while in opposing dugouts, two Major League Baseball (MLB) managers are teaming up with Mastercard and Stand Up To Cancer (SU2C) to battle malignancies such as ovarian cancer. Alex Cora and Dave Roberts, All-Star skippers of the Boston Red Sox and Los Angeles Dodgers, respectively, are uniting…

This post was originally published on this site Sleep apnea can drive the development of aggressive multiple myeloma in mice resistant to the cancer, a study found, suggesting that the sleep disorder is a modifiable risk factor for this disease. Treating sleep apnea, breathing that starts and stops repeatedly during sleep (also known as chronic intermittent…

This post was originally published on this site Maintenance treatment with Zejula (niraparib) extended the time without disease worsening in women with advanced ovarian cancer who had responded to first-line chemotherapy, according to updated results of a Phase 3 trial. The study, called PRIMA (NCT02655016), is a randomized, double-blind clinical trial assessing Zejula as a…

This post was originally published on this site An investigational antibody-drug conjugate made of the HER2-targeting antibody trastuzumab (marketed as Herceptin and others) attached to a kind of chemotherapy compound has demonstrated notable efficacy in heavily treated patients with breast and other cancer types, a Phase 1 trial showed. “Trastuzumab duocarmazine in locally advanced and…

This post was originally published on this site There is a popular maxim that reads, “Things often get worse before they get better.” It’s one applied to various scenarios in life, but for those of us going through treatment for cancer, it means getting sicker in order to finally get better. This applies especially to…

This post was originally published on this site According to a new study comparing older and younger sarcoidosis patients, elderly people with sarcoidosis tend to have more severe disease and worse clinical outcomes. The study, “Elderly sarcoidosis: A comparative study from a 42-year single-centre experience,” was published in the journal Respiratory Medicine.  Sarcoidosis usually presents in…

This post was originally published on this site MSN Labs, the parent company of Novadoz Pharmaceuticals, is launching a generic version of Janssen Pharmaceuticals’ approved therapy Zytiga (abiraterone acetate) in the U.S. market. Following its approval by the U.S. Food and Drug Administration (FDA), the generic abiraterone acetate 250mg tablets will be available for the…

This post was originally published on this site The bad news? It was cancer. The good news? It was in the early stages, a baby tumor at 1.5 cm. It’s hard to believe something so small has such a big impact. My friend Lauren went to a routine mammogram and was surprised when she heard…